CHANGE IN CONTROL AND EXECUTIVE SEVERANCE PLAN AGREEMENTChange in Control and Executive Severance Plan Agreement • October 7th, 2021 • Oncocyte Corp • In vitro & in vivo diagnostic substances • Delaware
This Change in Control and Executive Severance Plan Agreement (the “Agreement”) is entered into by and between Gisela A. Paulsen, MPharm (“you” or “your”) and Oncocyte Corporation (the “Company”). This Agreement has an effective date of October 4, 2021 (the “Effective Date”). The Board has authorized the Company to enter into this Agreement in order for you to become a Covered Employee participant under the Oncocyte Corporation Change in Control and Severance Plan (the “Plan”). This Agreement enumerates the Plan benefits that may be provided to you as a Covered Employee as referenced in Section II of the Plan. All provisions of this Agreement are subject to and governed by the terms of the Plan. In the event of any conflict in terms between the Plan and this Agreement, the terms of the Plan shall prevail and govern.
